ONCT News and Press, Oncternal Therapeutics Inc. From 08/10/23

2023-08-10 20:43:04 ET Oncternal Therapeutics, Inc. (ONCT) Q2 2023 Earnings Conference Call August 10, 2023 05:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO Conference Call Participants Carl By...

2023-08-10 16:02:52 ET Oncternal Therapeutics press release ( NASDAQ: ONCT ): Q2 GAAP EPS of -$0.15 beats by $0.02 . Revenue of $0.11M (-42.1% Y/Y) misses by $0.06M . Cash runway extended into 2025, with $45.5 million in cash, cash equivalents and short-term ...

Obtained U.S. FDA IND clearance for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor signaling inhibitors Dosed the first patient in our Phase 1/2 study for ONCT-808, our ROR1...

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2023 financial results after the U.S. financial markets c...

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the receipt of a Study May Proceed letter from the U.S. Food and Drug Administration (FDA), ...

SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study ...

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that Dr. James Breitmeyer, Oncternal’s President and Chief Executive Officer will pres...

2023-05-04 22:53:04 ET Oncternal Therapeutics, Inc. (ONCT) Q1 2023 Results Conference Call May 04, 2023 5:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO Conference Call Participants Hartaj Singh...

2023-05-04 16:52:52 ET Oncternal Therapeutics press release ( NASDAQ: ONCT ): Q1 GAAP EPS of -$0.20 in-line. Revenue of $0.2M (-71.4% Y/Y) beats by $0.06M . For further details see: Oncternal Therapeutics GAAP EPS of -$0.20 in-line, revenue of $0.2M beats by ...

Phase 1/2 study initiated for ONCT-808, our autologous CAR-T targeting ROR1-expressing hematologic malignancies, with initial clinical data expected in late 2023 Final IND-enabling studies completed for ONCT-534, our novel dual-action androgen receptor inhibitor (DAARI), with expected IND...